{"id":2784,"date":"2019-10-08T00:51:33","date_gmt":"2019-10-07T22:51:33","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2784"},"modified":"2024-04-18T09:07:03","modified_gmt":"2024-04-18T07:07:03","slug":"grup-de-recerca-en-malalties-cardiovasculars-bio-heart","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-medicina-translacional\/programa-de-malalties-cardiovasculars-respiratories-sistemiques-i-denvelliment-cel%c2%b7lular\/grup-de-recerca-en-malalties-cardiovasculars-bio-heart\/","title":{"rendered":"Grup de Recerca en Malalties Cardiovasculars (BIO-HEART)"},"content":{"rendered":"\n
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O’Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM, DELIVER Trial Committees and I. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction<\/strong>. N. Engl. J. Med. 2022;387(12):1089-1098. doi:10.1056\/NEJMoa2206286.<\/p>\n Senage T, Paul A, Le Tourneau T, Fellah Hebia I, Vadori M, Bashir S, Galinanes M, Bottio T, Gerosa G, Evangelista A, Badano LP, Nassi A, Costa C, Cesare G, Manji RA, de Monchy CC, Piriou N, Capoulade R, Serfaty JM, Guimbretiere G, Dantan E, Ruiz Majoral A, du Fou GC, Ben Arye SL, Govani L, Yehuda S, Abramovitch SB, Amon R, Reuven EM, Atiya Nasagi Y, Yu H, Iop L, Casos K, Kuguel SG, Blasco Lucas A, Permanyer E, Sbraga F, Llatjos R, Moreno Gonzalez G, Sanchez Martinez M, Breimer ME, Holgersson J, Teneberg S, Pascual Gilabert M, Nonell Canals A, Takeuchi Y, Chen X, Manez R, Roussel JC, Soulillou JP, Cozzi E, Padler Karavani V. The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration<\/strong>. Nat. Med. 2022;28(2):283-294. doi:10.1038\/s41591-022-01682-w.<\/p>\n Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial<\/strong>. Nat. Med. 2022;28(3):568-574. doi:10.1038\/s41591-021-01659-1.<\/p>\n Moliner P, Comin Colet J. Iron deficiency and supplementation therapy in heart failure<\/strong>. Nat. Rev. Cardiol. 2022;19(9):571-572. doi:10.1038\/s41569-022-00747-0.<\/p>\n Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J, Comin Colet J, Ferreira JP, Mentz RJ, Nassif ME, Psotka MA, Tromp J, Brueckmann M, Blatchford JP, Salsali A, Voors AA. Effects of Empagliflozin on Symptoms, Physical Limitations and Quality of Life in Patients Hospitalized for Acute Heart Failure – Results From the EMPULSE Trial<\/strong>. Circulation. 2022;146(4):279-288. doi:10.1161\/CIRCULATIONAHA.122.059725.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t MCI21056. Estrategias preventivas integradoras para el c\u00e1ncer y las enfermedades cardiovasculares basadas en inteligencia artificial (IA ) Ministerio de Ciencia e Innovaci\u00f3n<\/strong>. Budget: 569250. 2022-2024. PI: Com\u00edn Colet, Josep.<\/p>\n MCI21056. TED 2021- CCSHARED – Artificial intelligence (AI) driven integrative preventive strategies for cancer and CV disease (ARTICCA)<\/strong>. Ministerio de Ciencia e Innovaci\u00f3n. Budget: 569250. 2022-2024. PI: Josep Comin.”<\/p>\n 18ACL013. Estudio Onyx ONE; un estudio aleatorizado y controlado con el stent Resolute Onyx y tratamiento de doble antiagregaci\u00f3n plaquetaria [DAPT] de Un mes para pacientes con alto riesgo de sangrado<\/strong>. Budget: 350800. 2018- . PI: Cequier Fillat, \u00c1ngel.<\/p>\n 20ACL119. HELIOS-B: ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO Y MULTIC\u00c9NTRICO PARA EVALUAR LA EFICACIA Y LA SEGURIDAD DE VUTRISIR\u00c1N EN PACIENTES CON AMILOIDOSIS CARDIACA POR TRANSTIRETINA (AMILOIDOSIS POR ATTR CON MIOCARDIOPAT\u00cdA)<\/strong>. Budget: 299745. 2020- . PI: Gonz\u00e1lez Costello, Jos\u00e9.<\/p>\n MCI22001. Clinical trial to evaluate the administration of ApTOLL in Acute Myocardial Infarction. APSTEMI. Ministerio de Ciencia e Innovaci\u00f3n<\/strong>. Budget: 259100,89. 2022-2025. PI: G\u00f3mez Hospital, Joan Antoni.<\/p>\n\t\t\t\t\n Grup de Recerca en Malalties Cardiovasculars (BIO-HEART) Resum Aquest grup, focalitzat en la investigaci\u00f3 cl\u00ednica de les malalties i riscos cardiovasculars, presenta una \u00e0mplia experi\u00e8ncia en un camp de gran rellev\u00e0ncia, ja que les malalties cardiovasculars continuen sent la major causa de mortalitat al m\u00f3n occidental tant en dones com en homes. El grup estudia […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":568,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-12 20:57:50","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2784"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=2784"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2784\/revisions"}],"predecessor-version":[{"id":25442,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2784\/revisions\/25442"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/568"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=2784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n\t\tComin Colet, Josep \n\t<\/h4>\n
\n\t\t\n\t\tjcomin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n
\n\t\tComin Colet, Josep \n\t<\/h4>\n
\n\t\t\n\t\tjcomin@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGomez Lara, Josep\n\t<\/h4>\n
\n\t\t\n\t\tjgomezl@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tPiera Jimenez, Jordi\n\t<\/h4>\n
\n\t\t\n\t\tjpieraj@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n\t\t\t\t\n
\n\t\tAriza Sole, Albert\n\t<\/h4>\n
\n\t\t\n\t\taariza@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tEnjuanes Grau, Cristina\n\t<\/h4>\n
\n\t\t\n\t\tcenjuanes@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tGonzalez Costello, Jos\u00e9\n\t<\/h4>\n
\n\t\t\n\t\tjgcostello@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tTajes Ordu\u00f1a, Marta\n\t<\/h4>\n
\n\t\t\n\t\tmtajes@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFerreiro Gutierrez, Jose Luis\n\t<\/h4>\n
\n\t\t\n\t\tjferreiro@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tIborra Ortega, Elena\n\t<\/h4>\n
\n\t\t\n\t\teiborra@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\t@JosepComin\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@AlbertAriza3\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@DrJLFerreiro\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCaps de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport de gesti\u00f3\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tEstudiants\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tCol\u00b7laboradors\/es\t\t\t\t<\/a>\n\t\t\t\t\t\tCaps de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\t8M: Cada 8 minuts mor una dona per malaltia cardiovascular<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t08\/03\/2024\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tQuatre grups de recerca de l’IDIBELL reben finan\u00e7ament de La Marat\u00f3 de 3Cat dedicada a les malalties cardiovasculars<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/11\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl Programa d’Insufici\u00e8ncia Card\u00edaca Comunit\u00e0ria de la GTMS aconsegueix reduir les hospitalitzacions i les morts als 90 i als 180 dies de l’alta<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t29\/08\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn estudi conclou que l’atenci\u00f3 integrada territorial de les persones amb insufici\u00e8ncia card\u00edaca redueix l’impacte de la desigualtat socioecon\u00f2mica<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t24\/08\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn nou estudi busca solucions per minimitzar les complicacions en els trasplantaments card\u00edacs<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t12\/06\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa recerca en mHealth de Bellvitge, destacada al congr\u00e9s m\u00e9s rellevant en l’\u00e0mbit mundial d’Insufici\u00e8ncia Card\u00edaca<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t26\/05\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tL’Hospital de Bellvitge i l’IDIBELL lideren un assaig cl\u00ednic estatal per reduir l’impacte de les infeccions en els pacients trasplantats de cor<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t31\/03\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl Hospital de Bellvitge, IDIBELL i Astrazeneca proven una aplicaci\u00f3 que monitoritza la insufici\u00e8ncia card\u00edaca mitjan\u00e7ant la veu<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t06\/03\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn grup d’excel\u00b7l\u00e8ncia integrat per investigadors de l’IDIBELL i professionals de Cardiologia de l’HUB s’integra al CIBER de Malalties Cardiovasculars<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t03\/02\/2023\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl Dr. Josep Com\u00edn, coautor de sengles publicacions a Nature Medicine i JACC sobre un nou f\u00e0rmac contra la insufici\u00e8ncia card\u00edaca<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/01\/2023\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"